Newsgroup: it.salute
Titolo: SMAIL Disfunzioni sessuali: AMPAKINES una nuova molecola

Salve a tutti,
Ho "pescato" questo comunicato stampa. Si parla di un nuova molecola,
l'Ampakines, per il trattamento delle disfunzioni sessuali in caso di
malattie neurodegenerative come il morbo di Alzheimer, il morbo di
Parkinson, la Sclerosi Multipla ed altre malattie del sistema nervoso
centrale.
Bye, Alessio
***
Friday February 11, 8:01 am Eastern Time
Company Press Release
SOURCE: Cortex Pharmaceuticals, Inc.
Cortex Pharmaceuticals Receives Notice of Allowance For A Broad Patent to
Treat Sexual Dysfunction
- Company Also Receives Additional Patents for Several New Families of
AMPAKINE Structures -
IRVINE, Calif., Feb. 11 /PRNewswire/ -- Cortex Pharmaceuticals, Inc. (OTC
Bulletin Board: CORX - news) today announced that it had received Notice of
Allowance from the United States Patent and Trademark Office for additional
claims that cover the use of AMPA receptor modulating compounds, regardless
of structure, to treat sexual dysfunction. This patent application covers
Cortex's AMPAKINES®, as well as compounds made by others that are positive
modulators of the AMPA receptor and which are useful for treating sexual
dysfunction.
``As animals and humans age, there is a slow, progressive loss of synaptic
connections in the brain, resulting in reduced communication between brain
cells or neurons. This loss of synapses may be accelerated in certain
neurodegenerative diseases including Alzheimer's disease, Parkinson's
disease, Multiple Sclerosis and other central nervous system diseases,''
said Vincent F. Simmon, Ph.D., President and Chief Executive Officer of
Cortex. ``One of the early signs of this loss of synapses is an increasing
difficulty in remembering information.''
``Another sign can be decreased libido in both males and females,'' Dr.
Simmon continued. ``Loss of libido is also associated with other central
nervous system diseases including depression and with chronic treatment with
a number of medications.'' AMPAKINES enhance synaptic communication by
increasing the normal effects of glutamate, the most prevalent
neurotransmitter in the brain. Research conducted at the University of
California, Irvine (UCI) demonstrated that treatment of elderly rodents with
AMPAKINES resulted in improved sexual performance in a battery of standard
animal assays for sexual function.
The inventors of this patent are Professors Gary Lynch, Ph.D. and Richard
Granger, Ph.D., both of UCI. Cortex has an exclusive license to the claims
covered by the patent.
``We are optimistic about developing this application with a pharmaceutical
partner,'' stated Dr. Simmon. ``The treatments that are currently available,
including Viagra®, are approved for males who have a peripheral problem such
as reduced circulation in the pelvic area due to disease or trauma. However,
these drugs do not restore sexual drive or libido and it is recognized that
Viagra does not provide benefit for all patients with sexual dysfunction. An
AMPAKINE may be useful in patients, whether male or female, with sexual
dysfunction due to reduced libido.''
It is estimated that sexual dysfunction increases from less than 10% of the
population under 50 to as much as 60% of males over age 70.
Cortex also received US Patent No. 5,985,871 invented by Gary Rogers, Ph.D.
Vice President, Pharmaceutical Discovery and Chris Marrs, Ph.D., a former
employee of the Company, which describes ``Benzoxazine Compounds for
Enhancing Synaptic Response.'' ``This patent will significantly increase the
number of proprietary compounds covered by Cortex's AMPAKINE family of AMPA
receptor modulators,'' Dr. Rogers stated. ``This patent is the result of our
continuing development of more potent AMPAKINES and is consistent with our
philosophy to seek patent protection on as many possible active molecules as
possible.''
``The issuance of these patents adds to our very strong proprietary position
of use patents and patents on important chemical structures that can be used
to enhance nerve cell communication in the brain,'' added Dr. Simmon.
Cortex has now received a total of eight issued and two allowed US patents
that cover the uses of AMPA receptor modulating technology and chemical
structures that are useful for this technology.
Cortex, located in Irvine, California, is a neuroscience company focused on
novel drug therapies for neurological and psychiatric disorders. The Company
is pioneering a class of proprietary pharmaceuticals called AMPAKINES, which
act to increase the strength of signals at connections between brain cells.
Aberrant neural connections or loss of these connections is believed to be
responsible for the memory and cognitive dysfunction associated with ageing
and Alzheimer's disease. Recent clinical studies at Massachusetts General
Hospital with CX516, one of Cortex's AMPAKINES, indicated improvements in
tests of memory and cognition in a battery of neuropsychiatric tests as well
as improvements of a number of clinical symptoms in patients with
schizophrenia who were being treated with clozapine.
    For Additional Information see:  
www.cortexpharm.com
    Viagra is a registered trademark of Pfizer Inc.
Note -- This press release contains forward-looking statements concerning
the Company's research and development activities and business development
plans. Actual results may differ materially, depending on a number of risk
factors, including the risks that the Company may be unable to secure
additional capital needed to continue its operations; that the Company may
be unable to arrive at corporate partnerships with larger pharmaceutical
companies on acceptable terms and therefore be required to independently
fund clinical development of AMPAKINES through the sale of additional equity
securities or otherwise; that the Company's proposed products may at any
time be found to be toxic or ineffective for any or all of their proposed
indications; that competitors may challenge or design around the Company's
patents or develop competing technologies; and that clinical studies may at
any point be suspended or take substantially longer than anticipated to
complete. As discussed in the Company's Securities and Exchange Commission
filings, the Company's proposed products would require additional research,
lengthy and costly clinical testing and regulatory approval.
SOURCE: Cortex Pharmaceuticals, Inc.
----------------------------------------------------------------------------

visitare il sito 
www.saluscenter.com
mubble ...non possono...  ...esse sono...
Cartesio: Discorso sul metodo
“Il primo (precetto) era di non accettare mai nessuna cosa per vera se prima
non l'avessi riconosciuta evidentemente essere tale [...] e di non
comprendere nei miei giudizi niente di piů di ciň che si presentasse cosě
chiaramente e distintamente al mio spirito che io non avessi alcuna
occasione di metterlo in dubbio”.
Le frasi del sig. Vanoli si commentano da sole. Consiglierei una completa ed
attenta lettura del "Discorso sul metodo" di Cartesio.
Alessio Renieri

 wrote in message
10n9h3g$c1l$1...@fe2.cs.interbusiness.it...


Signor Vanoli,
La scienza delle malattie è la patologia; essa studia la causa della
malattia (eziologia), il suo meccanismo e l'evoluzione (patogenesi), i segni
con cui si manifesta (semeiologia) e i mezzi per combatterla (terapia).
Determinare il tipo di malattia da cui è affetto un dato individuo significa
porre la diagnosi; determinarne l'evoluzione è fare la prognosi. Infine, la
conoscenza delle cause che la determinano porta a evitarle o a sopprimerle
(profilassi). Le malattie possono distinguersi in locali e generali, a
seconda se colpiscono una parte soltanto del corpo o l'intero organismo; in
acute o croniche, a seconda che i loro segni vengano accentuati in
un'evoluzione rapida che porta in pochi giorni alla guarigione o alla morte
o al contrario che siano meno spiccati e a evoluzione lenta, progressiva o
regressiva.
In primo luogo occorre distinguere le malattie congenite comprese nel codice
genetico del soggetto o indotte nel feto durante la vita intrauterina, da
quelle che vengono acquisite dopo la nascita, anche se il limite fra queste
malattie non sempre è nettamente definibile. Infatti molte volte una
malattia (ad es. la tubercolosi) si manifesta soltanto se l'individuo ha una
predisposizione congenita per tale malattia. Un criterio di classificazione
molto usato è quello eziologico che considera il fattore determinante e che
distingue: malattie traumatiche, derivanti da urti, ferite, compressione,
schiacciamento, ecc.; malattie dovute ad agenti fisici, come calore, freddo,
elettricità, radiazioni; malattie tossiche, provocate da veleni minerali
(arsenico, mercurio, basi o acidi, ecc.); malattie parassitarie, provocate
generalmente da parassiti animali e vegetali; malattie infettive, la cui
causa è da ricercarsi in un batterio patogeno (polmoniti, difterite,
tubercolosi, ecc.) o in un protozoo (malaria, sifilide, ecc.) o in un virus
(morbillo, poliomielite, rabbia, ecc.); malattie discrasiche, che sono
provocate da modificazioni degli scambi o da vizi di nutrizione (gotta,
litiasi, diabete, obesità, ecc.).
Le malattie possono anche essere classificate in relazione al processo
patologico predominante, distinguendo così ad es. malattie
infiammatorie(come l'appendicite), degenerative (come l'arteriosclerosi),
esantematiche (come il morbillo), oppure anche in base all'apparato,
all'organo o al tessuto colpito: malattie respiratorie, cardiache,
parenchimatiche, ecc., o alla funzione lesa.
Spero possa comprendere la completa *assurdità* (per non dire di peggio) del
suo "Protocollo della salute" e delle "pseudo-terapie" da lei proposte alla
luce di quanto esposto. Io ho cose ben più importanti da fare e non vorrei
perdere altro tempo con lei: le comunico che i suoi (deliranti) "reply" ai
miei messaggi saranno ignorati.
D.S. Alessio Renieri